Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15376005 | 0.87 | RORC (0.49) | GPR119PDE4BRORCMEN1KMT2A | |
| SCHEMBL6132207 | 0.86 | GPR119 (0.67) | GPR119PDE4BCYP2C9KMT2AKDM4E | |
| SCHEMBL10289613 | 0.85 | NR1H2 (0.49) | GPR119PDE4BRORCKDM4ENAMPT | |
| SCHEMBL8053119 | 0.84 | PDE4B (0.48) | PDE4BRORCMEN1KMT2AKDM4E | |
| SCHEMBL23119769 | 0.84 | RORC (0.44) | GPR119PDE4BRORCMEN1KMT2A | |
| SCHEMBL17736163 | 0.84 | GPR119 (0.53) | GPR119PDE4BRORCKMT2AKDM4E | |
| SCHEMBL20607546 | 0.84 | RORC (0.48) | GPR119PDE4BRORCKDM4ENAMPT | |
| SCHEMBL23091747 | 0.84 | NAMPT (0.51) | GPR119PDE4BRORCKDM4ENAMPT | |
| SCHEMBL21001067 | 0.83 | HDAC6 (0.54) | PDE4BRORCMEN1KMT2AKDM4E | |
| SCHEMBL20757468 | 0.82 | MEN1 (0.57) | PDE4BRORCMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2601190-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | AH USA 42 LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | GPR119 92/4885PDE4B 635/4885CYP2C9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.